Charles River Laboratories International, Inc. $CRL Shares Sold by Moore Capital Management LP

Moore Capital Management LP cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 91.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,892 shares of the medical research company’s stock after selling 39,342 shares during the quarter. Moore Capital Management LP’s holdings in Charles River Laboratories International were worth $883,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Glenmede Trust Co. NA increased its holdings in shares of Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares during the period. Mercer Global Advisors Inc. ADV lifted its position in shares of Charles River Laboratories International by 1.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after acquiring an additional 80 shares during the period. Advisory Services Network LLC raised its holdings in Charles River Laboratories International by 2.6% during the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the last quarter. Brown Miller Wealth Management LLC grew its stake in Charles River Laboratories International by 7.0% in the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock valued at $220,000 after acquiring an additional 84 shares during the last quarter. Finally, Contravisory Investment Management Inc. increased its stake in shares of Charles River Laboratories International by 1.5% during the 1st quarter. Contravisory Investment Management Inc. now owns 6,218 shares of the medical research company’s stock worth $1,073,000 after purchasing an additional 89 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. Morgan Stanley raised their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Finally, Mizuho set a $264.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Insiders Place Their Bets

In related news, EVP Shannon M. Parisotto sold 2,039 shares of Charles River Laboratories International stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total transaction of $599,710.68. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,413,834.84. The trade was a 29.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $289.02 on Tuesday. The firm has a market capitalization of $13.80 billion, a PE ratio of -59.59, a P/E/G ratio of 3.03 and a beta of 1.38. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a 50-day moving average price of $248.22 and a 200 day moving average price of $198.15. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $303.30.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period in the previous year, the firm earned $3.12 EPS. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.